Calcium Channel Blocker Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The Calcium Channel Blocker Market is expected to register a CAGR of 5.1% during the forecast period.

The pandemic had a significant effect on market growth. For instance, the research study from Nature Journal published in January 2022 reported that anxiety related to the COVID-19 pandemic was linked to a temporary rise in the morning sleep blood pressure (SBP) among older patients and increased risk of cardiovascular events throughout the 1-year follow-up. As a result, continuous blood pressure monitoring became necessary both during and after the pandemic, which increased the demand for calcium channel blockers. Additionally, several projects involving blood pressure were initiated in 2020-21 to improve and support blood pressure. For example, the American Heart Association received USD 32 million in December 2020 through a series of cooperative agreements with the United States Department of Health and Human Services for a national initiative to improve COVID-19-related health outcomes by reducing high blood pressure among racial and ethnic populations, who have higher rates of high blood pressure and are at increased risk for COVID-19 and severe chronic conditions such as heart disease. Thus, the market had a significant impact on the market studied. However, currently, the market studied has reached its pre-pandemic stage in terms of demand for the products and is believed to witness strong growth in coming years.

The increasing prevalence rate of cardiovascular diseases and changing lifestyles of people are expected to boost the calcium channel blocker market growth.

Various research studies have been published to provide insight into calcium channel blockers. For instance, according to a research study by PubMed published in May 2022, calcium channel blockers (CCBs) like amlodipine significantly increase the therapeutic responses to gemcitabine in orthotopic xenografts and transgenic models of pancreatic ductal adenocarcinoma by inhibiting prosurvival Epidermal Growth Factor Receptor (EGFR). Therefore, the use of calcium channel blockers is increasing in orthopedic xenografts.

Hypertension, often referred to as elevated blood pressure, is one of the major causes associated with heart disease. Increasing heart disease is another factor in market growth. For instance, according to a news release issued by Boehringer Ingelheim GmbH in August 2021, heart failure is a chronic, incapacitating cardio-renal-metabolic disease that affects about 60 million individuals or more worldwide. As the prevalence of heart failure continues to rise, new therapeutic options are desperately needed. As a result, there was a global demand for the pharmaceuticals available to treat hypertension, which fueled the rise of the market under investigation. Thus, the abovementioned factors are expected to increase the market growth.

However, product recalls in recent years may hinder the market growth.

Key Market Trends

Hospitals Segment Expected to Hold a Major Share in the Calcium Channel Blocker Market

A hospital also referred to as a medical centre, is a healthcare institution providing treatment with specialized medical and nursing staff and medical equipment. Factors such as increasing cases of hypertension, along with an increasing number of hospitals and initiatives by the public organization, are expected to increase the market growth. For instance, according to the American Hospital Association, 2021, the total number of all United States Hospitals was 6,090. More than 700 million individuals around the world have untreated hypertension, according to data updated by the World Health Organization (WHO) in August 2021, and 1.28 billion people worldwide had hypertension, a sharp increase over the previous few decades.

Additionally, hypertension considerably raises the risk of renal, heart, and brain problems, according to the WHO publication. As a result, there is an increase in demand for medications used to manage hypertension, which is anticipated to propel the segment's expansion. In August 2022, Prime Minister Narendra Modi inaugurated Amrita Hospital in Haryana, which is claimed to be India's largest private hospital with 2,600 beds. The super-speciality hospital is equipped with the latest healthcare facilities. With an increasing number of large hospitals, it is believed that the care provided to patients will also improve, which will boost the segment growth in the coming years.

Thus, the abovementioned factors are likely to increase the market growth.

North America Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global calcium Channel blocker market due to changing lifestyles among people and the increasing prevalence rate of cardiovascular diseases.

The adoption of a sedentary lifestyle has serious implications for the health of people and is known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. For instance, according to the Pan American Health Organization (PAHO) for 2021, ischemic heart disease and stroke were the leading causes of mortality and a significant factor in disability in the Americas. Cardiovascular diseases (CVD) are also one of the main causes of death and disability worldwide. According to the same source as above, ischemic heart disease is a significant cause of 73.6 fatalities per 100,000 people. In the Americas, 40.8 million disability-adjusted life years (DALYs) are caused each year by cardiovascular illnesses. Thus, to prevent such high mortality, the adoption of hypertension-prevention drugs is expected to increase. This is expected to increase market growth in the upcoming future.

The increasing burden of hypertension is augmenting the emergence of new initiatives by the government to cope with the condition. For instance, Mexico formally endorsed the HEARTS project in February 2020. The Pan American Health Organization/World Health Organization (PAHO/WHO) is supporting the effort, which aims to improve primary care-level hypertension prevention and management. The goal is to reduce the burden of chronic diseases and get closer to achieving the Sustainable Development Goals by 2030. Such a program is expected to increase the need for blood pressure medications in the nation, which will help to fuel the rising need for calcium channel blockers. Thus, the abovementioned factors are expected to increase the market growth.

Competitive Landscape

The calcium channel blocker market is fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies currently dominating the market include Pfizer Inc., Alvogen, Abbvie Inc., Exela, Pharma Sciences LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, and Arbor Pharmaceuticals LLC.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.